A patient on the Monjuvi trial saw lymph nodes shrink 85%, with stable results a year later, supporting the FDA’s recent ...

Celgene Corporation (($CELG)) announced an update on their ongoing clinical study. Celgene Corporation recently completed a Phase 3B study titled ...

While not FDA approved, rituximab combined with lenalidomide (Revlimid) has emerged as a potential chemotherapy-free first-line option for advanced follicular lymphoma.